Strategies for enzyme/prodrug cancer therapy.

@article{Xu2001StrategiesFE,
  title={Strategies for enzyme/prodrug cancer therapy.},
  author={Guang Xu and Howard L. McLeod},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2001},
  volume={7 11},
  pages={
          3314-24
        }
}
The selective activation of prodrug(s) in tumor tissues by exogenous enzyme(s) for cancer therapy can be accomplished by several ways, including gene-directed enzyme prodrug therapy (GDEPT), virus-directed enzyme prodrug therapy (VDEPT), and antibody-directed enzyme prodrug therapy (ADEPT). The central part of enzyme/prodrug cancer therapy is to deliver drug-activating enzyme gene or functional protein to tumor tissues, followed by systemic administration of a prodrug. Although each approach… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 79 CITATIONS

FILTER CITATIONS BY YEAR

2002
2019

CITATION STATISTICS

  • 5 Highly Influenced Citations

  • Averaged 5 Citations per year over the last 3 years

  • 43% Increase in citations per year in 2018 over 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 79 REFERENCES

The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies

  • W. A. Nenny, W. R. Wilson
  • J. Pharm. Pharmacol.,
  • 1998
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…